Acute myeloid leukemia (AML) is a rare pediatric cancer with approximately 10-15 diagnoses per year in Belgium. Despite a global increase in survival rates, they remain stagnant at 60-70%. In addition, current intensive treatment options face challenges such as relapse and short and long term side effects. Therefore, novel treatment options are of major importance.
Our research focuses on a newly identified immunotherapeutic target, TARP, in adult and pediatric AML patients. Both the evaluation of cytotoxic T-cells with TARP as target and the development of a TARP-directed AML nanobody will be addressed. With these new treatment options we aim to improve the survival rates, reduce the side effects of the treatments and improve the quality of life of children with AML.
- 2020-present: PhD candidate in Medicine and Health Sciences, Ghent University
- 2015-2020: Master of Science in Biomedical Sciences
- 2009-2015: Science – Mathematics, Sint-Jozefsinstituut college Torhout
Contact & links
- Lab address: Laboratory for Pediatric Hematology-Oncology and Stem Cell Transplantation, ingang 10 (route 1034), Ghent University Hospital, Corneel Heymanslaan 10, 9000 Ghent
- Lab for Pediatric Hematology-Oncology
- ORCID ID
- Jolien Vanhooren is interested to receive invitations for talks or presentations